文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

用基线炎症标志物及其抗生素反应排除COVID-19细菌合并感染

Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该回顾性队列研究以社区获得性肺炎(CAP)为参照,比较CAP与COVID-19患者的基线炎症标志物及抗生素治疗后的变化。结果发现CAP患者基线白细胞计数和C反应蛋白更高,且抗生素治疗48-72小时后CRP下降更明显。联合白细胞计数和CRP变化可区分CAP与COVID-19,有助于排除COVID-19患者的细菌合并感染并促进抗生素管理。

要点

  • CAP患者基线白细胞计数和CRP显著高于COVID-19患者。
  • CAP患者抗生素治疗48-72小时后CRP下降,而COVID-19患者CRP多上升。
  • 基线白细胞计数>8.2×10^6 cells/mL或CRP下降可识别94%的CAP病例。

核心结论

  • 在COVID-19患者中,基线白细胞计数未升高且抗生素治疗后CRP未下降,可排除细菌合并感染。

研究设计与样本

  • 回顾性队列研究,纳入Royal Free Hospital的106例CAP和619例COVID-19患者作为发现队列,Barnet Hospital的169例CAP和181例COVID-19患者作为独立验证队列。

主要发现

  • CAP患者基线白细胞计数中位数12.48(IQR 8.2-15.3)×10^6 cells/mL,COVID-19患者为6.78(IQR 5.2-9.5)×10^6 cells/mL,P<0.0001。
  • CAP患者基线CRP中位数133.5(IQR 65-221)mg/L,COVID-19患者为86.0(IQR 42-160)mg/L,P<0.0001。
  • 入院48-72小时CRP变化中位数CAP为-33(IQR -112至+3.5)mg/L,COVID-19为+14(IQR -15.5至+70.5)mg/L,P<0.0001。
  • 联合白细胞计数和ΔCRP的多元逻辑回归模型区分CAP与COVID-19的AUC为0.88(95%CI 0.83-0.94)。
  • 基线白细胞计数>8.2×10^6 cells/mL或CRP下降可识别94%的CAP病例,并在46%的COVID-19患者中排除细菌合并感染。

关键数值与推荐

  • 基线白细胞计数>8.2×10^6 cells/mL或CRP下降可识别94%的CAP病例。
  • 上述标准可在46%的COVID-19患者中排除细菌合并感染。

临床怎么用

  • 对于COVID-19患者,若基线白细胞计数未升高且抗生素治疗后CRP未下降,可考虑排除细菌合并感染,辅助抗生素管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 is infrequently complicated by bacterial co-infection, but antibiotic prescriptions are common. We used community-acquired pneumonia (CAP) as a benchmark to define the processes that occur in bacterial pulmonary infections, testing the hypothesis that baseline inflammatory markers and their response to antibiotic therapy could distinguish bacterial co-infection from COVID-19. METHODS: Retrospective cohort study of CAP (lobar consolidation on chest radiograph) and COVID-19 (PCR detection of SARS-CoV-2) patients admitted to Royal Free Hospital (RFH) and Barnet Hospital (BH), serving as independent discovery and validation cohorts. All CAP and >90% COVID-19 patients received antibiotics on hospital admission. RESULTS: We identified 106 CAP and 619 COVID-19 patients at RFH. Compared with COVID-19, CAP was characterized by elevated baseline white cell count (WCC) [median 12.48 (IQR 8.2-15.3) versus 6.78 (IQR 5.2-9.5) ×106 cells/mL, P < 0.0001], C-reactive protein (CRP) [median 133.5 (IQR 65-221) versus 86.0 (IQR 42-160) mg/L, P < 0.0001], and greater reduction in CRP 48-72 h into admission [median ΔCRP -33 (IQR -112 to +3.5) versus +14 (IQR -15.5 to +70.5) mg/L, P < 0.0001]. These observations were recapitulated in the independent validation cohort at BH (169 CAP and 181 COVID-19 patients). A multivariate logistic regression model incorporating WCC and ΔCRP discriminated CAP from COVID-19 with AUC 0.88 (95% CI 0.83-0.94). Baseline WCC >8.2 × 106 cells/mL or falling CRP identified 94% of CAP cases, and excluded bacterial co-infection in 46% of COVID-19 patients. CONCLUSIONS: We propose that in COVID-19, absence of both elevated baseline WCC and antibiotic-related decrease in CRP can exclude bacterial co-infection and facilitate antibiotic stewardship efforts.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mason CY, Kanitkar T, Richardson CJ, et al. Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. J Antimicrob Chemother. 2021. PMID: 33463683. doi:10.1093/jac/dkaa563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。